CATX · NYSE · ·
Next earnings: November 9, 2026
$2.62+4.6%Sep 29 close
Perspective Therapeutics, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2023 | 3 months toDec 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | -$3.8M | -$7.1M | +46.65% |
| Profit | -$26.8M | -$21.5M | -24.67% |
| Profit per share | -$0.22 | -$0.29 | +24.14% |
| Free Cash Flow | -$34.8M | -$21M | -66.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The team at Perspective is highly energized as we continue to build on the significant clinical progress we're making across our pipeline, prepare for our first Phase 3 study, and advance our flagship Chicago manufacturing facility toward completion,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity. The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors). The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224 Ra/ 212 Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Perspective Therapeutics, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Perspective Therapeutics, Inc. has no earnings call transcript available.